What are Oncology Clinical Trials?

Oncology clinical trials are research studies that test new cancer treatments in people. These trials can help doctors find new ways to improve cancer patients’ treatment and quality of life.

Several oncology clinical trials are based on discovering new drugs, while others test new combinations of existing drugs. Some studies test new ways to deliver cancer treatments, such as gene therapy or immunotherapy.  

The Global Oncology Clinical Trials Market:

The Oncology Clinical Trials Market is expected to register a parallel growth alongside the Global Market for Clinical Trials, which had a valuation of USD 54.24 billion in 2022 and is forecasted to reach USD 92.45 billion in 2023, with a compound annual growth rate (CAGR) of 6.9%. 

According to a market research report by Mordor Intelligence, for the studied period 2023-2028, the Global Oncology Clinical Trials Market is projected to have a CAGR of 5.4% and reach a total valuation of USD 16.63 billion by 2028, according to Business Wire. The largest market for oncology clinical trials is the North American market, whereas the fastest-growing region is Asia-pacific, with a CAGR of 7.4%. Several reasons behind this emerging market are the rising cancer incidence, increased investment in R&D, government support, and technological advancements.

What is the Role of CROs in Oncology Clinical Trials?

Faster Study Startup: CROs can expedite the study startup process by leveraging their established network of experienced investigators and research sites. They already have pre-existing relationships with oncology centers, which can help accelerate site selection and patient recruitment processes.

Expertise in Oncology: Full-Service CROs, like NoyMed, have extensive experience conducting cancer-related trials. Professionals at NoyMed, deeply understand the unique challenges and complexities associated with oncology research, such as diverse cancer types, targeted therapies, immunotherapies, and personalized medicine. 

Oncology-Specific Regulatory Knowledge: Regulatory requirements for oncology clinical trials can be complex and vary depending on the region. CROs with extensive experience in the field are well-versed in these regulations and can ensure compliance with local and international guidelines.

Data Collection and Management:  Accurate and reliable data collection is critical in oncology trials, especially when evaluating survival outcomes and disease progression. NoyMed CRO provides expert biostatistics, data management, and statistical programming solutions, giving precedence to accurate and reliable data collection, in-depth statistical analysis, and regulatory submission-ready reports creation. NoyMed’s biometrics professionals register an average of 45-50% decrease in CDISC file delivery time compared to the industry average. 

How to Select a CRO for Oncology Clinical Trials?

Evaluating Expertise:  Look for CROs with a proven track record in conducting oncology clinical trials and checking their experience with similar study designs and therapeutic areas. A CRO with expertise in oncology will have a deeper understanding of the challenges and intricacies of conducting these trials. NoyMed CRO has completed 29 successful studies in oncology. 

Investigator and Site relationships: Considering a CRO’s track record in establishing and maintaining strong relationships with investigators and clinical trial sites. A CRO with established site connections can help with faster patient recruitment and enrollment.

Vendor-Sponsor Relationships: Focusing on vendor-sponsor relationships is crucial for the successful execution of clinical trials. A strong and collaborative partnership can significantly impact the trial’s efficiency, data quality, and overall success. 

Timelines and Quality of Delivering a Project: The complex nature of oncology trials demands rigorous adherence to timelines to meet crucial milestones, such as patient recruitment, data collection, and safety reporting. Patient recruitment in oncology clinical trials is a challenging and time-consuming process. Due to the solid network of investigators and patients, NoyMed CRO’s experts manage to conduct the patient recruitment process faster than the industry average, thus delivering oncology projects in the fastest possible timelines.  Additionally, maintaining a high-quality standard throughout the trial is vital for generating reliable and clinically relevant data, ensuring an accurate assessment of the investigational treatment’s efficacy and safety in the oncology patient population.

Conclusion:

Oncology clinical trials are crucial in advancing cancer treatment and improving patients’ quality of life. Contract Research Organizations (CROs) like NoyMed play a vital role in expediting study startups, providing oncology expertise, navigating complex regulatory requirements, and ensuring accurate data collection and management. Selecting the right CRO with a proven track record, strong investigator and site relationships, collaborative partnerships, and a commitment to timelines and quality is essential for successful oncology clinical trials.

Sources:

  • Mordor Intelligence – “ONCOLOGY CLINICAL TRIALS MARKET SIZE & SHARE ANALYSIS – GROWTH TRENDS & FORECASTS (2023 – 2028)”
  • Business Wire – “Global $16.63 Billion Oncology Clinical Trials Markets to 2028 by Phase; Study Design; Cancer Type; Competitive Landscape”
  • Grand View Research – “Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Cancer Type, By Region, And Segment Forecasts, 2020 – 2027”